LOGIN  |  REGISTER
Surmodics

NRx Pharmaceuticals (NASDAQ: NRXP) Stock Quote

Last Trade: US$0.47 -0.06 -10.96
Volume: 2,525,831
5-Day Change: -2.70%
YTD Change: 2.59%
Market Cap: US$43.620M

Latest News From NRx Pharmaceuticals

Four potential near-term milestones, including data from two clinical trials, an NDA filing and a share dividend RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announces its anticipated financial results for the quarter and year ended December 31, 2023 and provides the following summary of its... Read More
Common Stock Will Begin Trading on Split-Adjusted Basis on April 2, 2024 RADNOR, Pa. , March 28, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become... Read More
RADNOR, Pa. , March 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024 , via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases... Read More
RADNOR, Pa. , March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt , Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024 , at the Blavatnik School of Government in... Read More
RADNOR, Pa. , March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024 , via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases... Read More
61.4% (56,781,354) of eligible shares voted 94.4% of votes were cast in favor of the resolution RADNOR, Pa. , March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the results of the vote held during today's Special Meeting of Shareholders. The meeting was called to vote on a proposal to give the Company's... Read More
NRx Pharmaceuticals Board of Directors has authorized its Chairman, CEO, and management to take all necessary steps to affect the Dividend and Royalty Rights to NRXP Shareholders and applicable warrant holders Dividend is intended to distribute 49% of HOPE Therapeutics stock and a Royalty Right for 1% of Ketamine sales made by HOPE Effective date to be declared as soon as all required legal, accounting, and regulatory steps... Read More
Initiative is intended to protect shareholder value through continued compliance with Nasdaq listing rules and elimination of naked short sales positions in the Company's securities The Company is contemplating a reverse split, if needed to maintain NASDAQ listing compliance, to be accompanied by change in corporate name and CUSIP number Company has retained former SEC enforcement leadership to notify leading brokerages of... Read More
Company to receive first allocation of ketamine for sale by month end Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply Important step toward goal of providing full suite of supply options, to ultimately include an FDA approved, and widely... Read More
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter Study maintained 95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported. Positive data and FDA comment would trigger the... Read More
NRx Pharmaceuticals received approximately $1.0 million in cash from an existing investor Shares were sold at $0.38 , a 26.7% premium the recent share offering, along with one common 5-year warrant ( $0.40 /share strike) Share purchase will assist the Company in achieving milestones across the development pipeline including Suicidal Depression, Suicidal Bipolar Depression and Chronic Pain data, as well as general corporate... Read More
In the news release, NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock, issued 27-Feb-2024 by NRx Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the correction removes language inadvertently included in the headline and body of the original press release. The complete, corrected release follows: NRx Pharmaceuticals, Inc. Announces Pricing of... Read More
RADNOR, Pa. , Feb. 27, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $0.30 per share, for aggregate gross proceeds of approximately $1,500,000 million , prior... Read More
RADNOR, Pa. , Feb. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company") , a clinical-stage biopharmaceutical company, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering of a limited number of shares. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and... Read More
Presentation available on NRx Pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/ KEY UPDATES ARE AS FOLLOWS: NRx management is proposing to award 50% of founding shares in HOPE Therapeutics to current shareholders together with a royalty coupon with an expected ex-dividend date in the near future, all subject to board approval Dividend to be available to all shareholders who sign a covenant not to engage... Read More
HOPE shares currently owned by NRXP with planned share dividend to existing NRXP shareholders HOPE has now completed initial manufacture of Ketamine for IV infusion and plans to file FDA New Drug Application for treatment of acute suicidality upon demonstration of 2-year shelf stability (expected Q2 2024) HOPE plans to file patient-level data from two well-controlled clinical trials comparing ketamine to placebo in patients... Read More
Companies continue to work collaboratively to advance NRX-101 through registrational trials NRx remains eligible for an additional $324 million in development and sales milestones, as well as tiered double-digit royalties upon approval and commercialization of NRX-101. Payment materially extends the Company's cash runway RADNOR, Pa. , Feb. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx... Read More
Companies continue to work collaboratively to advance NRX-101 in bipolar depression with suicidality Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its phase 2b /3 trial of NRX-101 in suicidal treatment-resistant bipolar depression. The readout for this trial is anticipated in Q2 of this year." Productive partnership aims to accelerate NRX-101 to patients in need Lotus further... Read More
HOPE Therapeutics is dedicated to bringing NRX-100 (IV Ketamine) for Suicidal Depression to patients Company to be initially owned by NRx and current NRx shareholders via a planned tax-free dividend A New Drug Application (NDA) for NRX-100 is expected to be filed in 1H24 Initiating actions to gain a public listing Shareholder meeting planned for February 7, 2024 , is cancelled, and will be rescheduled, if necessary; Company... Read More
Exceeded originally target enrollment (70) with n=74 Last patient, last visit expected in approximately six weeks; data to follow shortly thereafter Positive data triggers milestone payment from Alvogen, as previously announced. RADNOR, Pa. , Jan. 22, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced completion of... Read More
RADNOR, Pa. , Jan. 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for suicidal depression, chronic pain, and PTSD, today announced that on January 16, 2024 , the Company was notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq Hearings Panel (the "Panel") granted the Company's request for the transfer of... Read More
NRX-101 has demonstrated potent activity against resistant urinary pathogens upon FDA review QIDP designation grants Priority Review and an additional 5 years of additional product exclusivity 3 million Americans develop complicated Urinary Tract Infection (cUTI) each year at a cost that ranges from $4497 to $17,431 with a high rate of antibiotic resistance and need for inpatient hospitalization 1 Unlike many... Read More
The benefits of ketamine are clear, but so are the risks Ketamine has now demonstrated clear superiority to placebo and non-inferiority to electroshock therapy in randomized trials encompassing more than 1,000 patients NRx to file a New Drug Application for ketamine to treat suicidal depression in 2024 in US and EU RADNOR, Pa. , Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals",... Read More
Company to present full compliance plan, based on achieving clinical milestones, to Nasdaq on January 4, 2024 RADNOR, Pa. , Jan. 2, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced an update on plans to achieve compliance with Nasdaq market requirements related to minimum bid price and total Market Value of Listed... Read More
Former Inspector General, US Dept. of Health and Human Services Former Assistant US Attorney for the Eastern District of Virginia Nationally recognized attorney in highly regulated industries; healthcare specialist RADNOR, Pa. , Dec. 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that Janet Rehnquist has been... Read More
Ketamine, an NMDA blocker, was highly effective compared to active comparator in rapidly reducing Suicidality (p=0.0003) This study represents the second well-controlled trial NRx has licensed supporting the use of IV Ketamine in suicidal depression NRx plans to present the data from these two trials to FDA in support of a New Drug Application to be filed in q1 2024 RADNOR, Pa. , Dec. 19, 2023 /PRNewswire/ -- NRx... Read More
"Study May Proceed" letter received from FDA Potential to initiate registrational study in 2024 RADNOR, Pa. , Dec. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that its Investigational New Drug Application (IND) for the use of NRX-101, the company's patented combination of D-cycloserine and lurasidone, for... Read More
RADNOR, Pa. , Dec. 13, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, announced their 2023 Annual Meeting of Stockholders (the "Annual Meeting") to be held on December 19, 2023, at 11:00 a.m., Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/am2023 . Management will discuss the items detailed in the... Read More
RADNOR, Pa. , Dec. 11, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the Company will be participating in-person at the LifeSci Partners Corporate Access Event for three days from January 8 th through the 10 th in San Francisco . 2024 promises to be a year of substantial growth that will likely include the... Read More
RADNOR, Pa. , Nov. 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt , Founder and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the Noble Capital Markets' 19th Annual Emerging Growth Investor Conference on Monday, December 4th, 2023 , at the College of... Read More
Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted 70 patients in the Phase 2b /3 trial of NRX-101 in Treatment Resistant Bipolar Depression; enrollment to continue through November to increase study power; last patient visit expected in January. Data expected to be released shortly thereafter Opened the Investigational... Read More
RADNOR, Pa. , Nov. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its third quarter 2023 financial results after the market closes on Tuesday, November 14, 2023 , via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases . The Company will... Read More
No current FDA-approved formulation of ketamine for treatment of depression and suicidality Partners are developing a proprietary, tamper and diversion-resistant formulation and packaging Finished drug with two-year shelf stability targeted for November 2024 , pending FDA approval Partners aim to submit New Drug Application by March 1, 2024 RADNOR, Pa. and WEST COLUMBIA, S.C. , Nov. 6, 2023 /PRNewswire/ -- NRx... Read More
FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application Intravenous Ketamine has become widely used for treating depression and suicidality but has never been presented to FDA for approval Potential to file New Drug Application for Ketamine in 2024 based on existing clinical data and newly-developed, modern commercial manufacturing protocols Further information is anticipated to be... Read More
"Study May Proceed" letter received from FDA IND preclinical requirements are consistent with studies already in progress to support treatment of Bipolar Depression Potential to initiate registrational studies in 2024, pending receipt of data from already-completed DOD-funded trial of D-cycloserine RADNOR, Pa. , Oct. 26, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a... Read More
Previously announced data sharing agreement for intravenous ketamine Newly available data highlight the need for a labeled form of IV ketamine that can qualify for insurance reimbursement Need for intravenous ketamine is heightened by recent failure of intranasal ketamine to treat suicidality. Currently approved esketamine is not available for patients with bipolar depression The importance of appropriately labeled... Read More
RADNOR, Pa. , Oct. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt , Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the 8th Annual Dawson James Conference on Thursday, October 12th, 2023 , at the Wyndam Grand Jupiter at Harbourside Place, in Jupiter... Read More
Allows initiation of the NRX-101 commercial development to treat Chronic Pain Company plans to seek Fast Track and Breakthrough Therapy Designations from FDA while awaiting near-term results of Dept of Defense-funded trial RADNOR, Pa. , Oct. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that FDA has given... Read More
Focus on implications of the recent Data Sharing Agreement relating to a landmark trial of Ketamine in the treatment of Suicidal Depression NMDA antagonist highly effective in Bipolar subgroup (p<0.001) RADNOR, Pa. , Sept. 20, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company posted a new... Read More
RADNOR, Pa. , Sept. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard , J.D., Chief Executive Officer and Dr. Jonathan Javitt , Chief Scientist of NRx Pharmaceuticals, will present a company overview at the Sidoti Virtual Small Cap Conference on Thursday, September 21, 2023 , at 9:15AM ET.... Read More
HealthStocksHub
Ketamine, an NMDA blocker, was highly effective in Bipolar subgroup (p<0.001) NRx plans to present the data to FDA with a goal of identifying a path to an NDA RADNOR, Pa. , Sept. 15, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company,... Read More
Industry veteran Richard Narido joins the NRx Pharmaceuticals management team RADNOR, Pa. , Sept. 14, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement (the "Agreement") with LS Associates, a division of LifeSci Advisors, LLC ("LSA"), pursuant to which LSA will provide... Read More
RADNOR, Pa. , Sept. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard , J.D., Chief Executive Officer and Dr. Jonathan Javitt , Chief Scientist of NRx Pharmaceuticals, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation is... Read More
NRX-101 demonstrated potent antibacterial effect against antibiotic-resistant pathogens in culture medium and in an artificial urine model D-cycloserine (DCS), a key component of NRX-101, was originally developed as an anti-infective in the 1950's but was replaced by antibiotics that have since lost effectiveness against complicated Urinary Tract Infections (cUTI) In an era when 90% of cUTI pathogens demonstrate resistance... Read More
IND builds on previously-published, preliminary evidence of efficacy Filing is supported by robust manufacturing, pre-clinical and clinical data already reviewed by FDA for NRX-101 associated with treatment of bipolar depression RADNOR, Pa. , Aug. 30, 2023 /PRNewswire/ - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced submission an... Read More
NRx Pharmaceuticals received approximately $1.2 million in cash from existing investors Preferred shares to sold at $0.40 ; shares convert to one common share and one common warrant ( $0.40 / strike) after six months Share purchase will assist the Company in development of NRX-101 in Suicidal Bipolar Depression and Chronic Pain and general corporate purposes RADNOR, Pa. , Aug. 29, 2023 /PRNewswire/ -- NRx Pharmaceuticals,... Read More
Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in suicidal bipolar depression; potential for up to $330 million in milestones and double-digit royalties Publication of STABIL-B trial in the International Journal of Bipolar Disorders: first oral antidepressant to demonstrate reduction in... Read More
RADNOR, Pa. , Aug. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company, today announced that it will release its second quarter 2023 financial results after the market closes on Monday, August 14, 2023 , via press release, which will be available on the Company's website at https://ir.nrxpharma.com/ . The Company will host a... Read More
NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian , a world leader in pain and D-Cycloserine (DCS) research, has joined the NRx Scientific Advisory Board RADNOR, Pa. , Aug. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it has made key advances in... Read More
RADNOR, Pa. , June 20, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Stephen Willard , J.D., Chief Executive Officer and Dr. Jonathan Javitt , Chief Scientist of NRx Pharmaceuticals, will present a company overview at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference. The presentation will... Read More
RADNOR, Pa. , June 9, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock. In a concurrent private placement, the Company... Read More
RADNOR, Pa. , June 6, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into definitive agreements for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock in a registered direct offering. In a concurrent private placement, the... Read More
RADNOR, Pa. , June 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it will host a corporate and strategic update conference call on Monday, June 5, 2023 at 8:30 a.m. EDT . A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/news-events/ir-calendar . An... Read More
Enrollment continues in the Phase 2b /3 clinical trial evaluating NRX-101 in Suicidal Treatment-Resistant Bipolar Depression; data expected in 4Q 2023 National educational campaign launched to further accelerate enrollment in Breakthrough Therapy Designation meeting for NRX-101 in Suicidal Treatment-Resistant Bipolar Depression with the U.S. FDA planned for 2Q 2023; on track to report topline clinical data in 4Q 2023 Ended... Read More
RADNOR, Pa. , May 10, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it is rescheduling its first quarter quarterly investor conference call previously scheduled for Thursday, May 11, 2023 at 4:30pm ET to Tuesday, May 16, 2023 at 8:30am ET , due to scheduling conflicts. The Company's first quarter 2023... Read More
RADNOR, Pa. , April 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, a Delaware Corporation, today announced that it will release its first quarter 2023 financial results after the market closes on Thursday, May 11, 2023 , via press release, which will be available on the Company's website at https://ir.nrxpharma.com/ . The... Read More
Over the past 12 months, the Company reinitiated its psychiatry development program post pandemic, transferred manufacturing of NRX-101 to the US, and initiated a clinical trial in suicidal treatment-resistant bipolar depression, which was recently reviewed by the independent Data Safety Monitoring Board (DSMB) The DSMB identified no safety or futility signals in the first 50 patients with Suicidal Treatment-Resistant... Read More
The independent Data Safety Monitoring Board recommended continuation of patient enrollment as planned No safety or futility signals were reported in the first 50 patients This patient population could represent up to 1 million bipolar depression patients in the US and represents a portion of the indication expansion recommended in recent correspondence with the FDA Trial has been upgraded to a Phase 2b /3 study that may be... Read More
RADNOR, Pa. , March 17, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. ( Nasdaq: NRXP ) ("NRx Pharmaceuticals", the "Company"), a clinical-stage CNS biopharmaceutical company, a Delaware Corporation, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Thursday, March 30, 2023 , via press release, which will be available on the Company's website at... Read More
NRx Pharmaceuticals received approximately $2.9 million in cash from existing investors. Offering will assist the Company to initiate its National Treatment Protocol and Safety Database for NRX-101 for Treatment-Resistant Bipolar Depression with Risk of Self Harm. RADNOR, Pa. , March 9, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage CNS biopharmaceutical... Read More
Company receives notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat bipolar depression with acute and subacute suicidality; This new patent represents a third patent family, that now totals 48 issued patents worldwide with 42 additional pending patent applications. Patent covers the use of NRX-101 to treat patients suffering from... Read More
FDA discussed a broader indication of "treatment of recently acutely suicidal patients" with Bipolar Depression. This broader indication does not require ketamine as the only stabilization agent. The Company estimates this substantially increases the addressable acute population for its treatment. FDA encouraged NRX to request a Breakthrough Therapy Planning Meeting for NRX-101. FDA suggested the NRX-101 clinical development... Read More
The Independent Data Safety Monitoring Board identified no safety concerns and issued a recommendation to continue trial enrollment. No treatment-related Serious Adverse Events with first 50 enrolled clinical trial participants RADNOR, Pa. , Feb. 2, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today reported the... Read More
RADNOR, Pa. , Jan. 19, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101. In response to a request for Type C guidance on the chemistry, manufacturing... Read More
RADNOR, Pa. , Jan. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6 th Annual Neuroscience Innovation Forum by Sachs Associates ("6 th... Read More
First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received Breakthrough Therapy Designation and a Special Protocol Assessment ("SPA") for this trial helping to mitigate risks and accelerate the timing of this NRX-101 development program First trial site has been contracted with others expected in near future, first dosing of patients... Read More
Ad hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa. , Dec. 20, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage central nervous system biopharmaceutical company, today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and... Read More
HealthStocksHub
Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairs Focused psychiatry practice expert in PTSD, Affective Disorders and Schizophrenia Proven track record in research as an investigator and academic grant-funded researcher Visiting Scholar at Stanford University ,... Read More
RADNOR, Pa. , Dec. 2, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it received written notice on December 1, 2022 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450(a)(1) (which requires the... Read More
Astria Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB